Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, significantly impacting patients' quality of life. Recent advances in immunological and molecular biological studies have identified numerous potential therapeutic targets for vitiligo, paving the way for novel treatment strategies. This article reviews the advancements in researching novel immunotherapy targets such as the JAK/ STAT pathway, PDE-4, Wnt/β-catenin pathway, and IL-15, along with their respective targeted drugs. The article aims to provide insights into the clinical translation of future therapeutic targets for vitiligo.
